GenSight Biologics S.A. (FRA:G49N)

Germany flag Germany · Delayed Price · Currency is EUR
0.111
-0.016 (-12.74%)
At close: Dec 4, 2025
-59.49%
Market Cap 18.00M
Revenue (ttm) 945.00K
Net Income (ttm) -15.12M
Shares Out n/a
EPS (ttm) -0.13
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 53,118
Average Volume 2,875
Open 0.097
Previous Close 0.127
Day's Range 0.097 - 0.111
52-Week Range 0.093 - 0.309
Beta n/a
RSI 44.83
Earnings Date Mar 24, 2026

About GenSight Biologics

GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ, a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2012
Employees 16
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol G49N
Full Company Profile

Financial Performance

In 2024, GenSight Biologics's revenue was 2.63 million, a decrease of -11.44% compared to the previous year's 2.96 million. Losses were -14.00 million, -46.60% less than in 2023.

Financial Statements

News

There is no news available yet.